News & Media

August 22, 2023

News Brief: WEX Pharmaceuticals Inc. Announces Addition Of Intellectual Property For Its Novel Development And Use Of Tetrodotoxin (TTX) To Relieve Pain

Read more

March 21, 2023

News Brief: WEX Pharmaceuticals Inc. Enrolls In Korea As Part Of The Multinational Phase 2B Clinical Trial Evaluating The Efficacy And Safety Of Halneuron® In The Treatment Of Chemotherapy-Induced Neuropathic Pain

Read more

February 8, 2023

News Brief: WEX Pharmaceuticals Inc. Announces Management Changes

Read more

January 3, 2023

News Brief: WEX Pharmaceuticals Inc. Enrolls The First Patient In The Phase 2B Clinical Trial Evaluating The Efficacy And Safety Of Halneuron® In The Treatment Of Chemotherapy-Induced Neuropathic Pain

Read more

November 30, 2022

News Brief: Wex Pharmaceuticals Inc. Announces Authorization For The Conduct Of A Chemotherapy-induced Neuropathic Pain Clinical Trial In China, Singapore, Taiwan, Korea, Usa, And Canada

Read more

September 22, 2022

News Brief: Wex Pharmaceuticals Inc. Announces A Scientific Poster Presentation At The IASP World Congress On Pain On Its Lead Compound, Halneuron®

Read more

August 31, 2022

News Brief: Wex Pharmaceuticals Inc. Announces Abstract And Poster Presentation At The IASP World Congress On Pain On The Lead Compound, TTX (Halneuron )®

Read more

April 30, 2021

News Brief: Publication of Two Papers Using Halneuron®

Read more

1 2 3